Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 7/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.37 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.36 |
| ▸ | TET3 | O43151 | 1/20 | 0.36 |
| ▸ | FBXL19 | Q6PCT2 | 1/20 | 0.36 |
| ▸ | CXXC5 | Q7LFL8 | 1/20 | 0.36 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.36 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.36 |
| ▸ | CXXC4 | Q9H2H0 | 1/20 | 0.36 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30505085 | 1.00 | AKR1C1 (0.52) | AKR1C1KMT2AHDAC4THRBTDP1 | |
| SCHEMBL8107105 | 0.94 | AKR1C1 (0.55) | AKR1C1KMT2AHDAC4THRBTDP1 | |
| SCHEMBL30991214 | 0.82 | HDAC4 (0.46) | AKR1C1HDAC4CYP2D6HSD11B1 | |
| SCHEMBL21582415 | 0.80 | CYP2D6 (0.50) | CYP2D6 | |
| SCHEMBL29573088 | 0.80 | CYP2D6 (0.50) | CYP2D6 | |
| SCHEMBL15502375 | 0.79 | HDAC4 (0.42) | KMT2AHDAC4HSD11B1 | |
| SCHEMBL15108974 | 0.79 | AKR1C1 (0.55) | AKR1C1KMT2AHDAC4THRBTDP1 | |
| SCHEMBL696669 | 0.78 | AKR1C1 (0.42) | AKR1C1KMT2AHDAC4 | |
| SCHEMBL8104865 | 0.77 | HDAC4 (0.44) | AKR1C1KMT2AHDAC4THRBTDP1 | |
| SCHEMBL4284674 | 0.76 | HDAC4 (0.59) | AKR1C1KMT2AHDAC4THRBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3577099-B1 | A NOVEL PROCESS FOR THE SYNTHESIS OF 1-ARYL-1-TRIFLUOROMETHYLCYCLOPROPANES | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-01-24 | — | — | EP | disclosed |
| US-20230293522-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-09-21 | — | — | US | disclosed |
| US-20230293522-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-09-21 | — | — | US | disclosed |
| CN-110234622-B | Novel process for the synthesis of 1-aryl-1-trifluoromethyl cyclopropane | 爱杜西亚药品有限公司 | 2023-07-04 | — | — | CN | disclosed |
| EP-3901159-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | Millennium Pharmaceuticals, Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| EP-3517112-B1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | MILLENNIUM PHARM INC (US) | 2021-04-07 | — | — | EP | disclosed |
| US-10780090-B2 | Heteroaryl compounds useful as inhibitors of SUMO activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2020-09-22 | — | — | US | disclosed |
| CN-110234622-A | Novel process for the synthesis of 1-aryl-1-trifluoromethylcyclopropane | 爱杜西亚药品有限公司 | 2019-09-13 | — | — | CN | disclosed |
| EP-3517112-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | Millennium Pharmaceuticals, Inc. (US) | 2019-07-31 | — | — | EP | disclosed |
| US-10335410-B2 | Heteroaryl compounds useful as inhibitors of sumo activating enzyme | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| EP-2483252-A2 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | Amira Pharmaceuticals, Inc. (US) | 2012-08-08 | — | — | EP | disclosed |
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| CN-102282124-A | Biphenylacetamide derivative | — | 2011-12-14 | — | — | CN | disclosed |
| EP-2374790-A1 | BIPHENYLACETAMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2011-10-12 | — | — | EP | disclosed |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-15 | — | — | US | disclosed |
| WO-2011041694-A2 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | WO | disclosed |
| WO-2011041694-A2 | COMPOUNDS AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | AMIRA PHARMACEUTICALS, INC. (US) | 2011-04-07 | — | — | WO | disclosed |
| CN-101012241-B | Benzyl-position-substituted oxazoline phosphine ligand with chirality center, synthetic method and application | SHANGHAI INST ORGANIC CHEM | 2010-11-17 | — | — | CN | disclosed |
| CN-101012241-A | Benzyl-position-substituted oxazoline phosphine ligand with chirality center, synthetic method and application | SHANGHAI INST ORGANIC CHEM (CN) | 2007-08-08 | — | — | CN | disclosed |
| US-4859232-A | Substituted-aryl cyclopropanecarbonitriles and derivatives thereof as herbicide antidotes | MONSANTO COMPANY (US) | 1989-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | HRH3, KCNH3, BRPF3 | AKR1C1 485/4885KMT2A 78/4885HDAC4 638/4885 |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | HRH3, KCNH3, BRPF3 | AKR1C1 485/4885KMT2A 78/4885HDAC4 638/4885 |
| US-10335410-B2 | Heteroaryl compounds useful as inhibitors of sumo activating enzyme | SAE1, SUMO1, SUMO3 | AKR1C1 1646/4885KMT2A 993/4885HDAC4 969/4885 |
| US-20230293522-A1 | HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME | SAE1, SUMO1, SUMO3 | AKR1C1 1646/4885KMT2A 993/4885HDAC4 969/4885 |
| US-10780090-B2 | Heteroaryl compounds useful as inhibitors of SUMO activating enzyme | SAE1, SUMO1, SUMO3 | AKR1C1 1646/4885KMT2A 993/4885HDAC4 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.